Vivos Therapeutics
VVOS
28 hedge funds and large institutions have $861K invested in Vivos Therapeutics in 2023 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 0 increasing their positions, 4 reducing their positions, and 9 closing their positions.
0.03% less ownership
Funds ownership: 0.63% → 0.6% (-0.03%)
7% less funds holding
Funds holding: 30 → 28 (-2)
22% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 9
64% less capital invested
Capital invested by funds: $2.39M → $861K (-$1.53M)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
+$26.5K |
| 2 |
Wealth Enhancement Advisory Services
Plymouth,
Minnesota
|
+$16.1K |
| 3 |
HighTower Advisors
Chicago,
Illinois
|
+$5.63K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$2.79K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$60 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GGI
Godsey & Gibb Inc
Richmond,
Virginia
|
-$47.4K |
| 2 |
Two Sigma Investments
New York
|
-$32.3K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$29.9K |
| 4 |
VF
Virtu Financial
New York
|
-$26K |
| 5 |
Renaissance Technologies
New York
|
-$17K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
JP Morgan Chase
New York
| $5 | +$8 | +1 | New |
|
|
GGI
27
Godsey & Gibb Inc
Richmond,
Virginia
| – | -$47.4K | -3,720 | Closed |
|
|
28
Two Sigma Investments
New York
| – | -$32.3K | -2,532 | Closed |
|
|
VF
29
Virtu Financial
New York
| – | -$26K | -2,034 | Closed |
|
|
30
Renaissance Technologies
New York
| – | -$17K | -1,342 | Closed |
|
|
TRCT
31
Tower Research Capital (TRC)
New York
| – | -$12.5K | -983 | Closed |
|
|
TSS
32
Two Sigma Securities
New York
| – | -$6.32K | -495 | Closed |
|
33
Osaic Holdings
Scottsdale,
Arizona
| – | -$510 | -40 | Closed |
|
34
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$272 | -36 | -67% |
|
35
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$255 | -20 | Closed |
|
36
Simplex Trading
Chicago,
Illinois
| – | +$53 | +7 | New |
|
VVOS Hedge Fund Activity: Q3 2023 in Review
28 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Vivos Therapeutics (VVOS) for Q3 2023, worth a combined $861K — down 64% from $2.39M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of VVOS and 7 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 0 added.
The largest buyer was HRT Financial, opening a new position worth an estimated $26.5K. The largest seller was Godsey & Gibb Inc, exiting entirely with an estimated $47.4K sold.
- 28 institutional investors held Vivos Therapeutics (VVOS) as of Q3 2023, down from 30 in Q2 2023.
- Funds reported $861K of Vivos Therapeutics stock for Q3 2023, down 64% quarter-over-quarter.
- 7 funds opened new Vivos Therapeutics positions in Q3 2023 and 9 closed out, a net change of -2 holders.
- The largest Vivos Therapeutics buyer in Q3 2023 was HRT Financial, an estimated $26.5K added.
- The largest Vivos Therapeutics seller in Q3 2023 was Godsey & Gibb Inc, an estimated $47.4K sold.
Based on aggregated 13F filings for Q3 2023.